BioSpace News Archive

With a handful of well-established players that account for key market share, global artificial limbs market is highly consolidated in nature, states Transparency Market Research in a new report.

Transplant diagnostics is a medical sector that has grown at a rapid pace in the last few years as a result of the rising use of transplant operations for a variety of body parts.

The growing need for state-of-the-art drug delivery mechanisms is the prime component that’s creating ripples across the next generation nebulizers market across the forecast period of 2019-2027.

An oxygen concentrator refers to a gadget that is tasked with the job of concentrating oxygen from a gas supply.

The demand within the global market for desalting and buffer exchange has been rising on account of the rising popularity of chromatography experiments in the chemical industry.

With substantial strides in medical technology alongside the deployment of the Internet of Things across the healthcare sector, the infrastructural growth of the developed and developing nations has paved the way for the expansion of the global market for automated compound storage and retrieval.

There have been several technological advancements with regards to the collection of blood from animals and its processing methodologies around the globe.

Hutchison China MediTech Limited announces that the US FDA has granted Fast Track Designation for the development of fruquintinib, for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor biological therapy, and, if RAS wild-type, an anti-epidermal growth factor receptor therapy.

Infectivity assays carried out in collaboration with Glasgow University show that Affimer reagents prevent infection of human cells by a SARS-COV-2 model virus

Ascentage Pharma announced that Guangzhou Healthquest Pharma Co., Ltd, a wholly-owned subsidiary of Ascentage Pharma’s, has submitted a New Drug Application to the Center for Drug Evaluation of China National Medical Products Administration for HQP1351 for the treatment of patients with T315I-mutant chronic phase chronic myeloid leukemia and accelerated phase CML.